# US 2022/0011324 A1 · Method for determining the haemoglobin content of an erythroid cell

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0011324 A1
- Document ID: US20220011324A1
- Status: Published application
- Kind: A1
- Application number: 17/395,969
- Filed: 2021-08-06
- Published: 2022-01-13
- Earliest claimed: 2016-11-04
- Assignees: Universite Paris Est Creteil Val De Marne; Assistance Publique-Hopitaux de Paris; Etablissement Francais Du Sang; Institut National de la Sante et de la Recherche Medicale
- Applicants: Université Paris Est CréTeil Val De Marne; Assistance Publique - Hopitaux de Paris; éTablissement FrançAis Du Sang; Institut National de la Santé et de la Recherche Médicale
- Inventors: Marie CAMBOT; Gaetana Vandemeulebrouck; France Noizat Pirenne; Pablo Bartolucci; Marie Georgine Rakotoson; Frédéric Galacteros; Nicolas Hebert
- Web page: https://patentgrep.com/patent/US20220011324A1

## CPC

- G01N 33/72: involving blood pigments, e.g. haemoglobin, bilirubin {or other porphyrins; involving occult blood}
- G01N 33/721: {Haemoglobin}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- G01N 33/723: {Glycosylated haemoglobin}
- G01N 33/80: involving blood groups or blood types {or red blood cells (white blood cells G01N33/56972)}
- G01N 2333/805: Haemoglobins; Myoglobins
- G01N 2800/22: Haematology
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention concerns a method for determining, by flow cytometry, the hemoglobin content of each erythroid cell of a set of erythroid cells. This method applies in particular to determining the hemoglobin content of each red blood cell of a set of red blood cells. The invention also concerns a method for determining the amount of red blood cells transfused into a patient and for monitoring the therapeutic efficacy of a treatment for sickle cell disease or β-thalassemia.

## Claims

### Claim 1

A method for determining, in vitro, the content of at least one hemoglobin Hbx in each erythroid cell of a set of erythroid cells contained in a sample of erythroid cells, comprising the steps of:
a) isolating erythroid cells from the sample;
b) permeabilizing the membrane of the isolated erythroid cells;
c) labeling the at least one hemoglobin Hbx of the erythroid cells obtained in step b) with at least one anti-Hbx antibody conjugated to a fluorochrome capable of emitting a fluorescence;
d) measuring, by flow cytometry, the fluorescence intensity (MFI) of each erythroid cell of the set of erythroid cells;
e) determining the content of the at least one hemoglobin Hbx in each erythroid cell of the set of erythroid cells by comparing the fluorescence intensity of each red blood cell with a standard curve associating the fluorescence intensity measured for a red blood cell with the at least one hemoglobin Hbx content.

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein the membrane of the isolated erythroid cells is fixed before the permeabilization step.

### Claim 3 (depends on 1)

The method as claimed in claim 1, wherein said sample is a blood sample.

### Claim 4 (depends on 1)

The method as claimed in claim 1, wherein said fluorochrome is selected from the group consisting of phycoerythrin (PE), fluorescein, isothiocyanate, a derivative thereof or a combination thereof.

### Claim 5 (depends on 1)

The method as claimed in claim 1, wherein the at least one Hbx hemoglobin is at least one first hemoglobin Hbx1, at least one second hemoglobin Hbx2 and at least one n nth hemoglobin designated as Hbxn, said method comprising the steps of:
a) isolating erythroid cells from a sample;
b) permeabilizing the membrane of the isolated erythroid cells;
c1) labeling the at least one first hemoglobin Hbx1 of the erythroid cells obtained in step b) with at least one anti-Hbx1 antibody conjugated to a first fluorochrome capable of emitting a first fluorescence; labeling the at least one second hemoglobin Hbx2 of the erythroid cells obtained in step b) with at least one second anti-Hbx2 antibody conjugated to a second fluorochrome capable of emitting a second fluorescence; labeling the at least one nth hemoglobin Hbxn of the erythroid cells obtained in step b) with at least one anti-Hbxn antibody conjugated to a nth fluorochrome capable of emitting a nth fluorescence,
d1) measuring, by flow cytometry, the fluorescence intensity of each fluorescence emitted by the first, the second, the nth fluorochrome of each erythroid cell of a set of erythroid cells;
e1) determining the content of the at least one first hemoglobin Hbx1, the at least one second hemoglobin Hbx2, the at least one nth hemoglobin Hbxn in each erythroid cell of the set of erythroid cells by comparing each of the first, the second, the nth fluorescence intensities measured in step d1) with a first, a second and an nth standard curve associating the measured first, second, and nth fluorescence intensities for a red blood cell, with content of the at least one first hemoglobin Hbx1, the content of the at least one second hemoglobin Hb2 and the content of the nth hemoglobin Hbxn.

### Claim 6 (depends on 1)

The method as claimed in claim 1, wherein the at least one Hbx hemoglobin are n hemoglobins Hbx, designated as Hbxn, said method comprising the steps of:
a) isolating erythroid cells from a sample;
b) permeabilizing the membrane of the isolated erythroid cells;
c1) labeling the at least one first hemoglobin Hbx1 of the erythroid cells obtained in step b) with at least one anti-Hbx1 antibody conjugated to a fluorochrome;
d1) measuring, by flow cytometry, the fluorescence intensity (MFI) of each erythroid cell of a set of erythroid cells;
e1) determining the content of the at least one first hemoglobin Hbx1 in each erythroid cell of the set of erythroid cells by comparing the fluorescence intensity of each red blood cell with a standard curve associating the fluorescence intensity measured for a red blood cell with the first hemoglobin Hbx1 content;
f) iterating the set of steps c1)-e1) for each of the at least one second Hbx2 (steps c2)-e2)), at least one third Hbx3 (steps c3)-e3)) and nth Hbxn (steps cn)-en)) until the content of the n hemoglobins Hbx in each erythroid cell of the set of erythroid cells is determined.

### Claim 7 (depends on 1)

The method as claimed in claim 1, wherein said at least one anti-Hbx antibody is directed against at least one of the chains of the at least one hemoglobin Hbx that are selected from the group consisting of α, β, γ, δ, ε (chain, glycosylated derivatives thereof, blood disease variants thereof, mutated forms thereof, or a mixture thereof.

### Claim 8 (depends on 1)

The method as claimed in claim 1, wherein said at least one hemoglobin Hbx is selected from the group consisting of HbF, HbA, HbS and a combination thereof.

### Claim 9 (depends on 1)

The method as claimed in claim 1, wherein the membrane of the isolated erythroid cells is permeabilized with sodium dodecyl sulfate.

### Claim 10 (depends on 2)

The method as claimed in claim 2, wherein the membrane of the isolated erythroid cells is fixed with sodium azide and/or formaldehyde.

### Claim 11 (depends on 1)

The method as claimed in claim 1, wherein the content of the at least one hemoglobin Hbx is determined for each erythroid cell of a set of at least 10,000 erythroid cells.

### Claim 12 (depends on 1)

The method as claimed in claim 1, wherein the erythroid cells are red blood cells.

### Claim 13 (depends on 1)

The method as claimed in claim 1, wherein the content the at least one hemoglobin Hbx in each erythroid cell of the set of erythroid cells is expressed as a concentration relative to the volume of the erythroid cells.

### Claim 14 (depends on 12)

A method for determining, in vitro, an amount of red blood cells transfused into a patient suffering from sickle cell disease, alpha-thalassemia or beta-thalassemia, comprising:
a) determining the content of the at least one hemoglobin Hbx selected from the group consisting of HbA, HbF and HbS of each red blood cell of a set of red blood cells of a sample of red blood cells from the patient according to the method of claim 12;
b) using the results of step a) to determine the amount of red blood cells transfused into a patient, said transfused red blood cells having an HbF and/or HbS content substantially equal to zero (=0 pg) and or a content ratio of the HbS/(HbF+HbA) substantially equal to zero (=0).

### Claim 15 (depends on 12)

An in vitro method for monitoring the therapeutic efficacy of a Hematopoietic stem cell transplantation (HSCT) or of a treatment for myelodysplastic syndromes, sickle cell disease or for β-thalassemia, comprising:
a) obtaining a sample containing red blood cells from a patient having undergone a HSCT or a treatment for a myelodysplastic syndrome, sickle cell disease or for β-thalassemia;
b) determining the content of the at least one hemoglobin Hbx in each red blood cell of a set of red blood cells of said sample according to the method of claim 12;
c) using the results of step b) in the monitoring of the therapeutic efficacy of Hematopoietic stem cell transplantation (HSCT) or the treatment for sickle cell disease or for β-thalassemia, in which a therapeutic efficacy is observed when at least a predetermined percentage of the red blood cells of the set of red blood cells has a content of the at least one hemoglobin Hbx that increases or decreases at least 2%, at least 5%, at least 7%, at least 10%, at least 12%, at least 15%, or at least 20% compared to the same content prior to the HSCT or the treatment for myelodysplastic syndromes, sickle cell disease or for β-thalassemia.

### Claim 16 (depends on 12)

A method for treating sickle cell disease or β-thalassemia, comprising:
a) obtaining a sample containing red blood cells from a patient;
b) determining the at least one hemoglobin Hbx content selected from the group consisting of the HbF, HbA and HbS content of each red blood cell of a set of red blood cells of said sample according to the method of claim 12;
c) when at least a predetermined percentage of the red blood cells of the set of red blood cells has an HbS content which exceeds a HbS reference threshold, and/or when at least a predetermined percentage of the red blood cells of the set of red blood cells has an HbF and/or HbA content is below HbF and/or HbA reference threshold initiating an appropriate treatment in the patient.

### Claim 17 (depends on 16)

The method as claimed in claim 16, wherein at least 20% of the red blood cells of the set of red blood cells have an HbF content which is below the reference threshold.

### Claim 18 (depends on 17)

The method as claimed in claim 17, wherein the reference threshold is 2 pg or more.

### Claim 19 (depends on 17)

The method as claimed in claim 17, wherein the reference threshold is selected from the group consisting of 3 pg, 4 pg, 5 pg, 6 pg, 7 pg, 7.5 pg.

### Claim 20 (depends on 16)

The method as claimed in claim 16, wherein the suitable treatment is hydroxyurea and/or erythropoietin.

### Claim 21 (depends on 3)

The method as claimed in claim 3, wherein the blood sample is a human blood sample.
